Guardant Health (GH) recently experienced a significant boost in its stock value, driven by a crucial decision from UnitedHealth Group to expand coverage for its innovative Shield blood test, designed for colorectal cancer screening. This development led Bernstein SocGen Group to elevate its price target for Guardant Health, signaling increased confidence in the company's market potential. The expanded coverage unlocks a substantial new demographic for Guardant Health's diagnostic solution, reinforcing its position in the healthcare sector, despite lingering concerns about market valuation and insider trading activities.
The positive shift began with Bernstein SocGen Group's decision on July 2 to increase its price target for Guardant Health from $175 to $200 per share, while maintaining an 'Outperform' rating. This adjustment was a direct response to UnitedHealth Group, the nation's largest health insurer, announcing it would cover Shield as a primary screening option for millions of its members aged 45 and above. Shield offers an alternative to traditional colonoscopies and at-home stool tests, requiring only a simple blood draw for early detection of colorectal cancer.
This single policy change from UnitedHealth is projected to significantly broaden Guardant Health's accessible market. Bernstein's analysis suggests that this move alone could grant Guardant access to approximately 10 million newly reimbursed patients. Historically, when a major insurer like UnitedHealth adopts a new diagnostic tool, other insurers often follow suit within a few quarters, hinting at a potential cascade effect across the industry. This expectation led Bernstein to nearly double its 2030 revenue forecast for Shield from $770 million to around $1.5 billion, and its 2040 estimate to approximately $4.1 billion.
Beyond the UnitedHealth announcement, Guardant Health received additional positive news. In May, the FDA approved an expanded Guardant360 Liquid CDx panel, significantly increasing the range of genes it assesses. Furthermore, the American Cancer Society subsequently included Shield in its official screening guidelines, marking a substantial endorsement for the blood test's efficacy and role in early cancer detection. Guardant Health also became part of the Russell 1000 index during its June reconstitution, which can lead to increased investor interest and institutional buying.
Despite these promising developments, analysts and investors acknowledge potential risks. Investing.com's fair-value model indicates that Guardant Health's stock might currently be overvalued relative to its core financial health, given its trailing 12-month loss per share and deeply negative net margin. Additionally, company insiders have been net sellers of the stock over the past year, which could signal cautious sentiment. Competition also remains a factor, particularly from Exact Sciences' Cologuard, which dominates the at-home stool-based screening market. Moreover, the American Cancer Society notes that blood-based tests may be less reliable in detecting early-stage cancers compared to stool-based methods.
Looking ahead, Guardant Health's trajectory will largely depend on several key factors. The company anticipates more commercial insurers will follow UnitedHealth's lead, further expanding Shield's market penetration. A formal recommendation from the U.S. Preventive Services Task Force would also be a significant catalyst, though Bernstein had already factored this into its long-term projections. Investors will be closely watching Guardant's second-quarter earnings report, expected around July 29, 2026, for further insights into its financial performance and future outlook. The stock has already seen a substantial increase since its June dip, having quadrupled in value, indicating that much of the positive news has already been factored into its current price.
